Clinical trials: Prostate Cancer Recurrent
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00003517
- Testing
- antineoplaston A10, antineoplaston AS2-1, bicalutamide
- Where
- United States
- Sponsor
- Burzynski Research Institute
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer
Phase II trial to study the effectiveness of combination chemotherapy plus monoclonal antibody therapy in treating patients who have metastatic prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00016107
- Testing
- estramustine phosphate sodium, docetaxel, bevacizumab
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00039104
- Testing
- rebimastat, zoledronic acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent or metastatic prostate cancer.
- Trial name
- NCT00095667
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Cilengitide in Treating Patients With Metastatic Prostate Cancer
This randomized phase II trial is studying how well cilengitide works in treating patients with metastatic prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
- Trial name
- NCT00103337
- Testing
- cilengitide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Bone Metastases
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
BMS-275291 may stop the growth of prostate cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00040755
- Testing
- rebimastat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel
Drugs used in chemotherapy, such as SB-715992, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00096499
- Testing
- ispinesib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)
Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer).
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00005039
- Testing
- recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT00074022
- Testing
- GTI-2040, docetaxel, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
- Trial name
- NCT00109811
- Testing
- PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer
This phase I trial is studying the side effects and best dose of photodynamic therapy with lutetium texaphyrin in treating patients with locally recurrent prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT00005067
- Testing
- motexafin lutetium, photodynamic therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00512668
- Testing
- leuprolide acetate, goserelin acetate, bicalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Prostate Cancer
Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study
When given to men with recurrent prostate cancer, the investigators hypothesize that POMx is effective in slowing the rise of PSA as measured by PSA doubling time in men following initial therapy for prostate cancer.
- Trial name
- NCT01220817
- Testing
- 3 POMx capsules, 1 POMx capsule
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- POM Wonderful LLC
Biochemical Recurrent Prostate Cancer
Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer
Primary Outcome Measures: Decrease in rate of serum PSA rise Secondary Outcome Measures: Adherence to treatment regimens Quality of life as assessed by FACT-P at baseline and at 12 months of treatment Modulation of serum…
- Trial name
- NCT00596895
- Testing
- Isoflavone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Recurrent or Persistent Localized Carcinoma of the Prostate Following Radiation Therapy Failure
Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy
To assess by MR Imaging the lesions induced by WST09-mediated photodynamic therapy (PDT) in patients with recurrent or persistent localized prostate cancer following definitive radiotherapy using different light doses and…
- Trial name
- NCT00308919
- Testing
- WST09
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- STEBA France
Locally Recurrent Prostate Cancer
An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy
The purpose of this study is to determine the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
- Trial name
- NCT00686088
- Testing
- PRX302
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sophiris Bio Corp